Patient Square Capital led a series B round for the gene therapy developer that included existing corporate investor Dexcel Pharma.

Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, closed a $100m series B round on Wednesday that included pharmaceutical firm Dexcel Pharma.

The round was led by investment firm Patient Square Capital and also featured QVT Financial, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo, JDRF T1D Fund, Woodline Partners, CAM Capital, Hongkou Capital, Alumni Ventures and unnamed others.

Founded in 2019, Kriya is working on a fully integrated platform designed to reduce…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn